Pediatr Gastroenterol Hepatol Nutr.  2018 Jan;21(1):34-42. 10.5223/pghn.2018.21.1.34.

Higher Morbidity of Monogenic Inflammatory Bowel Disease Compared to the Adolescent Onset Inflammatory Bowel Disease

Affiliations
  • 1Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea. mjschj@snu.ac.kr

Abstract

PURPOSE
Monogenic inflammatory bowel disease (IBD) patients do not respond to conventional therapy and are associated with a higher morbidity. We summarized the clinical characteristics of monogenic IBD patients and compared their clinical outcomes to that of non-monogenic IBD patients.
METHODS
We performed a retrospective cohort study of all children <18 years old who were diagnosed with IBD between 2005 and 2016. A total of 230 children were enrolled. Monogenic IBD was defined as a presentation age less than 6 years old with confirmation of a genetic disorder. We subdivided the groups into monogenic IBD (n=18), non-monogenic very early-onset IBD (defined as patients with a presentation age <6 years old without a confirmed genetic disorder, n=12), non-monogenic IBD (defined as all patients under 18 years old excluding monogenic IBD, n=212), and severe IBD (defined as patients treated with an anti-tumor necrosis factor excluding monogenic IBD, n=92). We compared demographic data, initial pediatric Crohn disease activity index/pediatric ulcerative colitis activity index (PCDAI/PUCAI) score, frequency of hospitalizations, surgical experiences, and height and weight under 3rd percentile among the patients enrolled.
RESULTS
The initial PCDAI/PUCAI score (p < 0.05), incidence of surgery per year (p < 0.05), and hospitalization per year (p < 0.05) were higher in the monogenic IBD group than in the other IBD groups. Additionally, the proportion of children whose weight and height were less than the 3rd percentile (p < 0.05 and p < 0.05, respectively) was also higher in the monogenic IBD group.
CONCLUSION
Monogenic IBD showed more severe clinical manifestations than the other groups.

Keyword

Inflammatory bowel disease; Very early onset; Immunologic deficiency syndromes; Interleukin-10; Crohn disease

MeSH Terms

Adolescent*
Child
Cohort Studies
Colitis, Ulcerative
Crohn Disease
Hospitalization
Humans
Immunologic Deficiency Syndromes
Incidence
Inflammatory Bowel Diseases*
Interleukin-10
Necrosis
Retrospective Studies
Interleukin-10

Cited by  4 articles

Recent Advance in Very Early Onset Inflammatory Bowel Disease
Jung Ok Shim
Pediatr Gastroenterol Hepatol Nutr. 2019;22(1):41-49.    doi: 10.5223/pghn.2019.22.1.41.

Clinical Aspects and Treatments for Pediatric Inflammatory Bowel Diseases
Jin Soo Moon
Pediatr Gastroenterol Hepatol Nutr. 2019;22(1):50-56.    doi: 10.5223/pghn.2019.22.1.50.

Clinical aspects and treatments for pediatric inflammatory bowel diseases
Jin Soo Moon
Intest Res. 2019;17(1):17-23.    doi: 10.5217/ir.2018.00139.

Recent advance in very early-onset inflammatory bowel disease
Jung Ok Shim
Intest Res. 2019;17(1):9-16.    doi: 10.5217/ir.2018.00130.


Reference

1. Loddo I, Romano C. Inflammatory bowel disease: genetics, epigenetics, and pathogenesis. Front Immunol. 2015; 6:551.
Article
2. Seo JK. Pediatric Inflammatory Bowel Disease (IBD): phenotypic, genetic and therapeutic differences between early-onset and adult-onset IBD. Korean J Pediatr Gastroenterol Nutr. 2011; 14:1–25.
Article
3. Seo JK, Yeon KM, Chi JG. Inflammatory bowel disease in children: clinical, endoscopic, radiologic and histopathologic investigation. J Korean Med Sci. 1992; 7:221–235.
Article
4. Uhlig HH. Monogenic diseases associated with intestinal inflammation: implications for the understanding of inflammatory bowel disease. Gut. 2013; 62:1795–1805.
Article
5. Kotlarz D, Beier R, Murugan D, Diestelhorst J, Jensen O, Boztug K, et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology. 2012; 143:347–355.
Article
6. Muise AM, Xu W, Guo CH, Walters TD, Wolters VM, Fattouh R, et al. NADPH oxidase complex and IBD candidate gene studies: identification of a rare variant in NCF2 that results in reduced binding to RAC2. Gut. 2012; 61:1028–1035.
Article
7. Moran CJ, Walters TD, Guo CH, Kugathasan S, Klein C, Turner D, et al. IL-10R polymorphisms are associated with very-early-onset ulcerative colitis. Inflamm Bowel Dis. 2013; 19:115–123.
Article
8. Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schäffer AA, Noyan F, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009; 361:2033–2045.
Article
9. Ruemmele FM, El Khoury MG, Talbotec C, Maurage C, Mougenot JF, Schmitz J, et al. Characteristics of inflammatory bowel disease with onset during the first year of life. J Pediatr Gastroenterol Nutr. 2006; 43:603–609.
Article
10. Chouraki V, Savoye G, Dauchet L, Vernier-Massouille G, Dupas JL, Merle V, et al. The changing pattern of Crohn's disease incidence in northern France: a continuing increase in the 10- to 19-year-old age bracket (1988-2007). Aliment Pharmacol Ther. 2011; 33:1133–1142.
Article
11. Benchimol EI, Mack DR, Nguyen GC, Snapper SB, Li W, Mojaverian N, et al. Incidence, outcomes, and health services burden of very early onset inflammatory bowel disease. Gastroenterology. 2014; 147:803–813. quiz e14-5.
Article
12. Aloi M, Lionetti P, Barabino A, Guariso G, Costa S, Fontana M, et al. Phenotype and disease course of early-onset pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2014; 20:597–605.
Article
13. Bequet E, Sarter H, Fumery M, Vasseur F, Armengol-Debeir L, Pariente B, et al. Incidence and phenotype at diagnosis of very-early-onset compared with later-onset paediatric inflammatory bowel disease: a population-based study [1988-2011]. J Crohns Colitis. 2017; 11:519–526.
Article
14. Gupta N, Bostrom AG, Kirschner BS, Cohen SA, Abramson O, Ferry GD, et al. Presentation and disease course in early-compared to later-onset pediatric Crohn's disease. Am J Gastroenterol. 2008; 103:2092–2098.
Article
15. Gower-Rousseau C, Dauchet L, Vernier-Massouille G, Tilloy E, Brazier F, Merle V, et al. The natural history of pediatric ulcerative colitis: a population-based cohort study. Am J Gastroenterol. 2009; 104:2080–2088.
Article
16. Imielinski M, Baldassano RN, Griffiths A, Russell RK, Annese V, Dubinsky M, et al. Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet. 2009; 41:1335–1340.
Article
17. Flores A, Burstein E, Cipher DJ, Feagins LA. Obesity in inflammatory bowel disease: a marker of less severe disease. Dig Dis Sci. 2015; 60:2436–2445.
Article
18. Glocker E, Grimbacher B. Inflammatory bowel disease: is it a primary immunodeficiency? Cell Mol Life Sci. 2012; 69:41–48.
Article
19. Glocker EO, Frede N, Perro M, Sebire N, Elawad M, Shah N, et al. Infant colitis--it's in the genes. Lancet. 2010; 376:1272.
Article
20. Bader-Meunier B, Florkin B, Sibilia J, Acquaviva C, Hachulla E, Grateau G, et al. Mevalonate kinase deficiency: a survey of 50 patients. Pediatrics. 2011; 128:e152–e159.
Article
21. van der Burgh R, Ter Haar NM, Boes ML, Frenkel J. Mevalonate kinase deficiency, a metabolic autoinflammatory disease. Clin Immunol. 2013; 147:197–206.
Article
22. Galeotti C, Meinzer U, Quartier P, Rossi-Semerano L, Bader-Meunier B, Pillet P, et al. Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency. Rheumatology (Oxford). 2012; 51:1855–1859.
Article
23. Paul T, Birnbaum A, Pal DK, Pittman N, Ceballos C, LeLeiko NS, et al. Distinct phenotype of early childhood inflammatory bowel disease. J Clin Gastroenterol. 2006; 40:583–586.
Article
24. Mamula P, Telega GW, Markowitz JE, Brown KA, Russo PA, Piccoli DA, et al. Inflammatory bowel disease in children 5 years of age and younger. Am J Gastroenterol. 2002; 97:2005–2010.
Article
25. Tarrant KM, Barclay ML, Frampton CM, Gearry RB. Perianal disease predicts changes in Crohn's disease phenotype-results of a population-based study of inflammatory bowel disease phenotype. Am J Gastroenterol. 2008; 103:3082–3093.
Article
26. Shaoul R, Karban A, Reif S, Weiss B, Shamir R, Tamir A, et al. Disease behavior in children with Crohn's disease: the effect of disease duration, ethnicity, genotype, and phenotype. Dig Dis Sci. 2009; 54:142–150.
Article
Full Text Links
  • PGHN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr